Invention Grant
- Patent Title: Trimeric S1-CD40L fusion protein vaccine against Middle East respiratory syndrome-coronavirus
-
Application No.: US16201409Application Date: 2018-11-27
-
Publication No.: US10849972B2Publication Date: 2020-12-01
- Inventor: Anwar M. Hashem
- Applicant: King Abdulaziz University
- Applicant Address: SA Jeddah
- Assignee: King Adulaziz University
- Current Assignee: King Adulaziz University
- Current Assignee Address: SA Jeddah
- Agency: Oblon, McClelland, Maier & Neustadt, L.L.P.
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/12 ; C07K16/10 ; C12N7/00 ; A61K39/155 ; A61K39/215 ; A61P31/14 ; C07K14/705 ; C12N15/62
Abstract:
An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
Public/Granted literature
- US20200164058A1 TRIMERIC S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE EAST RESPIRATORY SYNDROME-CORONAVIRUS Public/Granted day:2020-05-28
Information query
